The findings Li and his colleagues have presented have opened an exciting door to development of new therapeutics to fight the disease by aiming their sights on the CLYD gene.
"These results tell us that we now have a key regulator to target," said Binghe Wang, Director of the GSU Center for Diagnostics and Therapeutics and GRA Eminent Scholar in Drug Discovery and a co-author of the study.
"If we can target CLYD with a focus on regulating its protein level or activity, we may be able to better control fibrosis," said Wang, also chair of the Department of Chemistry at GSU. "There is a huge clinical potential in saving the lives of these patients."
The results are published in "CLYD Negatively Regulates Transforming Growth Factor- Signaling via Deubiquitinating Akt," Nature Communications, DOI: 10.1038/ncomms1776. The journal is online at www.nature.com/ncomms/index.html.
Li said the support provided by the GRA is invaluable to the groundbreaking research performed by scientists on the project. Li was named as a GRA Eminent Scholar in 2010, and Lim came to Georgia State's CIII as a GRA Distinguished Investigator in 2011. Prior to Li and Lim, Wang was named as a GRA Eminent Scholar in 2003.
"These studies are collaborative, multi-disciplinary efforts," Li said. "The support from the GRA has allowed us to build state of the art facilities at Georgia State which have been essential to making this essential life-changing research possible."
|Contact: Jeremy Craig|
Georgia State University